Essential Oils and Their Constituents: An Alternative Source for Novel Antidepressants
Abstract
:1. Introduction
2. Pharmacological Management of Major Depression
3. Methodology
4. Clinical Effects of Essential Oils on Mood Depression
5. Antidepressant-Like Effects of Essential Oils: Evidence from Animal Studies
5.1. Asarum heterotropoides F. Schmidt (Aristolochiaceae)
5.2. Citrus limon L. Osbeck
5.3. Eugenia uniflora L.
5.4. Perilla frutescens L. Britton
5.5. Salvia sclarea L.
5.6. Syzygium aromaticum (L.) Merr. & L.M. Perry
5.7. Toona ciliata var. yunnanensis (C. DC.) C.Y. Wu
5.8. Valeriana wallichii DC.
6. Constituents from Essential Oils with Antidepressant-Like Activity
6.1. Isolated Constituents with Proposed Mechanisms of Antidepressant Action
6.2. Isolated Constituents without Antidepressant Mechanism of Action
7. Conclusions
Acknowledgments
Author Contributions
Conflicts of Interest
References
- American Psychiatric Press (APA). Diagnostic and Statistical Manual of Mental Disorders, 5th ed.; American Psychiatric Press: Washington, DC, USA, 2013. [Google Scholar]
- Ferrari, A.J.; Somerville, A.J.; Baxter, A.J.; Norman, R.; Patten, S.B.; Vos, T.; Whiteford, H.A. Global variation in the prevalence and incidence of major depressive disorder: A systematic review of the epidemiological literature. Psychol. Med. 2013, 43, 471–481. [Google Scholar] [CrossRef] [PubMed]
- Nemeroff, C.B.; Owens, M.J. Treatment of mood disorders. Nat. Neurosci. 2002, 5, 1068–1070. [Google Scholar] [CrossRef] [PubMed]
- Castrén, E. Is mood chemistry? Nat. Rev. Neurosci. 2005, 6, 241–246. [Google Scholar] [CrossRef] [PubMed]
- Björkholm, C.; Monteggia, L.M. BDNF—A key transducer of antidepressant effects. Neuropharmacology 2016, 102, 72–79. [Google Scholar] [CrossRef] [PubMed]
- Santarelli, L.; Saxe, M.; Gross, C.; Sunget, A.; Battaglia, F.; Dulawa, S.; Weisstaub, N.; Lee, J.; Duman, R.; Arancio, O.; et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003, 301, 805–809. [Google Scholar] [CrossRef] [PubMed]
- Berton, O.; Nestler, E.J. New approaches to antidepressant drug discovery: Beyond monoamines. Nat. Rev. Neuroscience 2006, 7, 137–151. [Google Scholar] [CrossRef] [PubMed]
- Bezerra, D.P.; Soares, A.K.; De Sousa, D.P. Overview of the role of vanillin on redox status and cancer development. Oxid. Med. Cell. Longev. 2016, 2016, 9734816. [Google Scholar] [CrossRef] [PubMed]
- Souto-Maior, F.N.; Fonsêca, D.V.; Salgado, P.R.; Monte, L.O.; de Sousa, D.P.; de Almeida, R.N. Antinociceptive and anticonvulsant effects of the monoterpene linalool oxide. Pharm. Biol. 2017, 55, 63–67. [Google Scholar] [CrossRef] [PubMed]
- De Sousa, D.P.; Lima, T.C.; Steverding, D. Evaluation of antiparasitc activity of Mentha crispa essential oil, its major constituent rotundifolone and analogues against Trypanosoma brucei. Planta Med. 2016, 82, 1346–1350. [Google Scholar] [CrossRef] [PubMed]
- De Sousa, D.P.; de Almeida Soares Hocayen, P.; Andrade, L.N.; Andreatini, R. A Systematic review of the anxiolytic-like effects of essential oils in animal models. Molecules 2015, 20, 18620–18660. [Google Scholar] [CrossRef] [PubMed]
- Kim, W.; Hur, M.H. Inhalation effects of aroma essential oil on quality of sleep for shift nurses after night work. J. Korean Acad. Nurs. 2016, 46, 769–779. [Google Scholar] [CrossRef] [PubMed]
- Lytle, J.; Mwatha, C.; Davis, K.K. Effect of lavender aromatherapy on vital signs and perceived quality of sleep in the intermediate care unit: A pilot study. Am. J. Crit. Care 2014, 23, 24–29. [Google Scholar] [CrossRef] [PubMed]
- Press-Sandler, O.; Freud, T.; Volkov, I.; Peleg, R.; Press, Y. Aromatherapy for the Treatment of Patients with Behavioral and Psychological Symptoms of Dementia: A Descriptive Analysis of RCTs. J. Altern. Complement. Med. 2016, 22, 422–428. [Google Scholar] [CrossRef] [PubMed]
- Forrester, L.T.; Maayan, N.; Orrell, M.; Spector, A.E.; Buchan, L.D.; Soares-Weiser, K. Aromatherapy for dementia. Cochrane Database Syst. Rev. 2014, 2, CD003150. [Google Scholar]
- Dong, S.; Jacob, T.J. Combined non-adaptive light and smell stimuli lowered blood pressure, reduced heart rate and reduced negative affect. Physiol. Behav. 2016, 156, 94–105. [Google Scholar] [CrossRef] [PubMed]
- Kasper, S.; Anghelescu, I.; Dienel, A. Efficacy of orally administered Silexan in patients with anxiety-related restlessness and disturbed sleep—A randomized, placebo-controlled trial. Eur. Neuropsychopharmacol. 2015, 25, 1960–1967. [Google Scholar] [CrossRef] [PubMed]
- Cordell, B.; Buckle, J. The effects of aromatherapy on nicotine craving on a U.S. campus: A small comparison study. J. Altern. Complement. Med. 2013, 19, 709–713. [Google Scholar] [CrossRef] [PubMed]
- Uehleke, B.; Schaper, S.; Dienel, A.; Schlaefke, S.; Stange, R. Phase II trial on the effects of Silexan in patients with neurasthenia, post-traumatic stress disorder or somatization disorder. Phytomedicine 2012, 19, 665–671. [Google Scholar] [CrossRef] [PubMed]
- Jimbo, D.; Kimura, Y.; Taniguchi, M.; Inoue, M.; Urakami, K. Effect of aromatherapy on patients with Alzheimer’s disease. Psychogeriatrics 2009, 9, 173–179. [Google Scholar] [CrossRef] [PubMed]
- De Sousa, D.P. Analgesic-like activity of essential oils constituents. Molecules 2011, 16, 2233–2252. [Google Scholar] [CrossRef] [PubMed]
- De Sousa, D.P. Bioactive Essential Oils and Cancer; Springer International Publishing: New York, NY, USA, 2015. [Google Scholar]
- Oliveira, F.A.; Andrade, L.N.; De Sousa, E.B.; De Sousa, D.P. Anti-ulcer activity of essential oil constituents. Molecules 2014, 19, 5717–5747. [Google Scholar] [CrossRef] [PubMed]
- Sobral, M.V.; Xavier, A.L.; Lima, T.C.; De Sousa, D.P. Antitumor activity of monoterpenes found in essential oils. Sci. World J. 2014, 2014, 953451. [Google Scholar] [CrossRef] [PubMed]
- Yim, V.W.; Ng, A.K.; Tsang, H.W.; Leung, A.Y. A review on the effects of aromatherapy for patients with depressive symptoms. J. Altern. Complement. Med. 2009, 15, 187–195. [Google Scholar] [CrossRef] [PubMed]
- Lee, Y.L.; Wu, Y.; Tsang, H.W.; Leung, A.Y.; Cheung, W.M. A systematic review on the anxiolytic effects of aromatherapy in people with anxiety symptoms. J. Altern. Complement. Med. 2011, 17, 101–108. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Setzer, W.N. Essential oils and anxiolytic aromatherapy. Nat. Prod. Commun. 2009, 4, 1305–1316. [Google Scholar] [PubMed]
- Fibler, M.; Quante, A. A case series on the use of lavendula oil capsules in patients suffering from major depressive disorder and symptoms of psychomotor agitation, insomnia and anxiety. Complement. Ther. Med. 2014, 22, 63–69. [Google Scholar]
- Diego, M.A.; Jones, N.A.; Field, T.; Hernandez-Reif, M.; Schanberg, S.; Kuhn, C.; McAdam, V.; Galamaga, R.; Galamaga, M. Aromatherapy positively affects mood, EEG patterns falertness and math computations. Int. J. Neurosci. 1998, 96, 217–224. [Google Scholar] [CrossRef] [PubMed]
- Conrad, P.; Adams, C. The effects of clinical aromatherapy for anxiety and depression in the high risk postpartum woman—A pilot study. Complement. Ther. Clin. Pract. 2012, 18, 164–168. [Google Scholar] [CrossRef] [PubMed]
- Lee, K.B.; Cho, E.; Kang, Y.S. Changes in 5-hydroxytryptamine and cortisol plasma levels in menopausal women after inhalation of clary sage oil. Phytother. Res. 2014, 28, 1599–1605. [Google Scholar] [CrossRef] [PubMed]
- Komori, T.; Fujiwara, R.; Tanida, M.; Nomura, J.; Yokoyama, M.M. Effects of citrus fragrance on immune function and depressive states. Neuroimmunomodulation 1995, 2, 174–180. [Google Scholar] [CrossRef] [PubMed]
- Han, P.; Han, T.; Peng, W.; Wang, X.R. Antidepressant-like effects of essential oil and asarone, a major essential oil component from the rhizome of Acorus tatarinowii. Pharm. Biol. 2013, 51, 589–594. [Google Scholar] [CrossRef] [PubMed]
- Park, H.J.; Lim, E.J.; Zhao, R.J.; Oh, S.R.; Jung, J.W.; Ahn, E.M.; Lee, E.S.; Koo, J.S.; Kim, H.Y.; Chang, S.; et al. Effect of the fragrance inhalation of essential oil from Asarum heterotropoides on depression-like behaviors in mice. BMC Complement. Altern. Med. 2015, 15, 43. [Google Scholar] [CrossRef] [PubMed]
- Komori, T.; Fujiwara, R.; Tanida, M.; Nomura, J. Potential antidepressant effects of lemon odor in rats. Eur. Neuropsychopharmacol. 1995, 5, 477–480. [Google Scholar] [CrossRef]
- Komiya, M.; Takeuchi, T.; Harada, E. Lemon oil vapor causes an anti-stress effect via modulating the 5-HT and DA activities in mice. Behav. Brain Res. 2006, 172, 240–249. [Google Scholar] [CrossRef] [PubMed]
- Lopes, C.L.M.; Sá, C.G.; de Almeida, A.A.; da Costa, J.P.; Marques, T.H.; Feitosa, C.M.; Saldanha, G.B.; de Freitas, R.M. Sedative, anxiolytic and antidepressant activities of Citrus limon (Burn) essential oil in mice. Die Pharm. 2011, 66, 623–627. [Google Scholar]
- Victoria, F.N.; de Siqueira, A.B.; Savegnago, L.; Lenardão, E.J. Involvement of serotoninergic and adrenergic systems on the antidepressant-like effect of E. uniflora L. leaves essential oil and further analysis of its antioxidant activity. Neurosci. Lett. 2013, 544, 105–109. [Google Scholar] [CrossRef] [PubMed]
- Seol, G.H.; Shim, H.S.; Kim, P.J.; Moon, H.K.; Lee, K.H.; Shim, I.; Suh, S.H.; Min, S.S. Antidepressant-like effect of Salvia sclarea is explained by modulation of dopamine activities in rats. J. Ethnopharmacol. 2010, 130, 187–190. [Google Scholar] [CrossRef] [PubMed]
- Guzmán-Gutiérrez, S.L.; Gómez-Cansino, R.; García-Zebadúa, J.C.; Jiménez-Pérez, N.C.; Reyes-Chilpa, R. Antidepressant activity of Litsea glaucescens essential oil: Identification of β-pinene and linalool as active principles. J. Ethnopharmacol. 2012, 143, 673–679. [Google Scholar] [CrossRef] [PubMed]
- Lim, W.C.; Seo, J.M.; Lee, C.I.; Pyo, H.B.; Lee, B.C. Stimulative and sedative effects of essential oils upon inhalation in mice. Arch. Pharm. Res. 2005, 28, 770–774. [Google Scholar] [CrossRef] [PubMed]
- Ji, W.W.; Li, R.P.; Li, M.; Wang, S.Y.; Zhang, X.; Niu, X.X.; Li, W.; Yan, L.; Wang, Y.; Fu, Q.; et al. Antidepressant-like effect of essential oil of Perilla frutescens in a chronic, unpredictable, mild stress-induced depression model mice. Chin. J. Nat. Med. 2014, 12, 753–759. [Google Scholar] [CrossRef]
- Yi, L.T.; Li, J.; Geng, D.; Liu, B.B.; Fu, Y.; Tu, J.Q.; Liu, Y.; Weng, L.J. Essential oil of Perilla frutescens-induced change in hippocampal expression of brain-derived neurotrophic factor in chronic unpredictable mild stress in mice. J. Ethnopharmacol. 2013, 147, 245–253. [Google Scholar] [CrossRef] [PubMed]
- Machado, D.G.; Cunha, M.P.; Neis, V.B.; Balen, G.O.; Colla, A.; Bettio, L.E.B.; Oliveira, A.; Pazini, F.L.; Dalmarco, J.B.; Simionatto, E.L.; et al. Antidepressant-like effects of fractions, essential oil, carnosol and betulinic acid isolated from Rosmarinus officinalis L. Food Chem. 2013, 136, 999–1005. [Google Scholar] [CrossRef] [PubMed]
- Viana, C.C.S.; Oliveira, P.A.; Brum, L.F.S.; Picada, J.N.; Pereira, P. Gamma-decanolactone effect on behavioral and genotoxic parameters. Life Sci. 2007, 80, 1014–1019. [Google Scholar] [CrossRef] [PubMed]
- Piccinelli, A.C.; Santos, J.A.; Konkiewitz, E.C.; Oesterreich, S.A.; Formagio, A.S.; Croda, J.; Ziff, E.B.; Kassuya, C.A. Antihyperalgesic and antidepressive actions of (R)-(+)-limonene, α-phellandrene, and essential oil from Schinus terebinthifolius fruits in a neuropathic pain model. Nutr. Neurosci. 2015, 18, 217–224. [Google Scholar] [CrossRef] [PubMed]
- Liu, B.B.; Luo, L.; Liu, X.L.; Geng, D.; Li, C.F.; Chen, S.M.; Chen, X.M.; Yi, L.T.; Liu, Q. Essential oil of Syzygium aromaticum reverses the deficits of stress-induced behaviors and hippocampal p-ERK/p-CREB/brain-derived neurotrophic factor expression. Planta Med. 2015, 81, 185–192. [Google Scholar] [CrossRef] [PubMed]
- Duan, D.; Chen, L.; Yang, X.; Tu, Y.; Jiao, S. Antidepressant-like effect of essential oil isolated from Toona ciliata Roem. var. yunnanensis. J. Nat. Med. 2015, 69, 191–197. [Google Scholar] [CrossRef] [PubMed]
- Sah, S.P.; Mathela, C.S.; Chopra, K. Involvement of nitric oxide (NO) signalling pathway in the antidepressant activity of essential oil of Valeriana wallichii Patchouli alcohol chemotype. Phytomedicine 2011, 18, 1269–1275. [Google Scholar] [CrossRef] [PubMed]
- Norte, M.C.; Cosentino, R.M.; Lazarini, C.A. Effects of methyl-eugenol administration on behavioral models related to depression and anxiety, in rats. Phytomedicine 2005, 12, 294–298. [Google Scholar] [CrossRef] [PubMed]
- Waters, R.P.; Rivalan, M.; Bangasser, D.A.; Deussing, J.M.; Ising, M.; Wood, S.K.; Holsboer, F.; Summers, C.H. Evidence for the role of corticotropin-releasing factor in major depressive disorder. Neurosci. Biobehav. Rev. 2015, 58, 63–78. [Google Scholar] [CrossRef] [PubMed]
- Bahi, A.; Al Mansouri, S.; Al Memari, E.; Al Ameri, M.; Nurulain, S.M.; Ojha, S. β-Caryophyllene, a CB2 receptor agonist produces multiple behavioral changes relevant to anxiety and depression in mice. Physiol. Behav. 2014, 135, 119–124. [Google Scholar] [CrossRef] [PubMed]
- Gertsch, J.; Leonti, M.; Raduner, S.; Racz, I.; Chen, J.Z.; Xie, X.Q.; Altmann, K.H.; Karsak, M.; Zimmer, A. Beta-caryophyllene is a dietary cannabinoid. Proc. Natl. Acad. Sci. USA 2008, 105, 9099–9104. [Google Scholar] [CrossRef] [PubMed]
- Marco, E.M.; García-Gutiérrez, M.S.; Bermúdez-Silva, F.J.; Moreira, F.A.; Guimarães, F.; Manzanares, J.; Viveros, M.P. Endocannabinoid system and psychiatry: In search of a neurobiological basis for detrimental and potential therapeutic effects. Front. Behav. Neurosci. 2011, 5, 63. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bhattacharya, A.; Derecki, N.C.; Lovenberg, T.W.; Drevets, W.C. Role of neuro-immunological factors in the pathophysiology of mood disorders. Psychopharmacology 2016, 233, 1623–1636. [Google Scholar] [CrossRef] [PubMed]
- Ling, Y.Z. Analysis of the volatile oil of Perilla frutescens drawing with two kinds of method by GC/MS. Chin. Condiment 2005, 30, 18–30. [Google Scholar]
- Ito, N.; Nagai, T.; Oikawa, T.; Yamada, H.; Hanawa, T. Antidepressant-like effect of l-perillaldehyde in stress-induced depression-like model mice through regulation of the olfactory nervous system. Evid. Based Complement. Altern. Med. 2011, 2011, 512697. [Google Scholar] [CrossRef] [PubMed]
- Guzmán-Gutiérrez, S.L.; Bonilla-Jaime, H.; Gómez-Cansino, R.; Reyes-Chilpa, R. Linalool and β-pinene exert their antidepressant-like activity through the monoaminergic pathway. Life Sci. 2015, 128, 24–29. [Google Scholar] [CrossRef] [PubMed]
- Coelho, V.; Mazzardo-Martins, L.; Martins, D.F.; Santos, A.R.; da Silva Brum, L.F.; Picada, J.N.; Pereira, P. Neurobehavioral and genotoxic evaluation of (-)-linalool in mice. J. Nat. Med. 2013, 67, 876–880. [Google Scholar] [CrossRef] [PubMed]
- Deng, X.Y.; Xue, J.S.; Li, H.Y.; Ma, Z.Q.; Fu, Q.; Qu, R.; Ma, S.P. Geraniol produces antidepressant-like effects in a chronic unpredictable mild stress mice model. Physiol. Behav. 2015, 152, 264–271. [Google Scholar] [CrossRef] [PubMed]
- Irie, Y.; Itokazu, N.; Anjiki, N.; Ishige, A.; Watanabe, K.; Keung, W.M. Eugenol exhibits antidepressant-like activity in mice and induces expression of metallothionein- III in the hippocampus. Brain Res. 2004, 1011, 243–246. [Google Scholar] [CrossRef] [PubMed]
- Tao, G.; Irie, Y.; Li, D.J.; Keung, W.M. Eugenol and its structural analogs inhibit monoamine oxidase A and exhibit antidepressant-like activity. Bioorg. Med. Chem. 2005, 13, 4777–4788. [Google Scholar] [CrossRef] [PubMed]
- Brocardo, P.S.; Budni, J.; Lobato, K.R.; Kaster, M.P.; Rodrigues, A.L. Antidepressant-like effect of folic acid: Involvement of NMDA receptors andl-arginine–nitric oxide–cyclic guanosine monophosphate pathway. Eur. J. Pharmacol. 2008, 598, 37–42. [Google Scholar] [CrossRef] [PubMed]
- Jesse, C.R.; Bortolatto, C.F.; Savegnago, L.; Rocha, J.B.; Nogueira, C.W. Involvement of l-arginine–nitric oxide–cyclic guanosine monophosphate pathway in the antidepressant-like effect of tramadol in the rat forced swimming test. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32, 1838–1843. [Google Scholar] [CrossRef] [PubMed]
- Crespi, F. The selective serotonin reuptake inhibitor fluoxetine reduces striatal in vivo levels of voltammetric nitric oxide (NO): A feature of its antidepressant activity? Neurosci. Lett. 2010, 470, 95–99. [Google Scholar] [CrossRef] [PubMed]
- Dhir, A.; Kulkarni, S.K. Involvement of l-arginine–nitric oxide–cyclic guanosine monophosphate pathway in the antidepressant-like effect of venlafaxine in mice. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31, 921–925. [Google Scholar] [CrossRef] [PubMed]
- Ghasemi, M.; Montaser-Kouhsari, L.; Shafaroodi, H.; Nezami, B.G.; Ebrahimi, F.; Dehpour, A.R. NMDA receptor/nitrergic system blockage augments antidepressant-like effects of paroxetine in the mouse forced swimming test. Psychopharmacology 2009, 206, 325–333. [Google Scholar] [CrossRef] [PubMed]
- Melo, F.H.; Moura, B.A.; de Sousa, D.P.; de Vasconcelos, S.M.; Macedo, D.S.; Fonteles, M.M.; Viana, G.S.; de Sousa, F.C. Antidepressant-like effect of carvacrol (5-Isopropyl-2-methylphenol) in mice: Involvement of dopaminergic system. Fundam. Clin. Pharmacol. 2011, 25, 362–367. [Google Scholar] [CrossRef] [PubMed]
- Yao, Y.; Huang, H.Y.; Yang, Y.X.; Guo, J.Y. Cinnamic aldehyde treatment alleviates chronic unexpected stress-induced depressive-like behaviors via targeting cyclooxygenase-2 in mid-aged rats. J. Ethnopharmacol. 2015, 162, 97–103. [Google Scholar] [CrossRef] [PubMed]
- Ji, W.W.; Wang, S.Y.; Ma, Z.Q.; Li, R.P.; Li, S.S.; Xue, J.S.; Li, W.; Niu, X.X.; Yan, L.; Zhang, X.; et al. Effects of perillaldehyde on alternations in serum cytokines and depressive-like behavior in mice after lipopolysaccharide administration. Pharmacol. Biochem. Behav. 2014, 116, 1–8. [Google Scholar] [CrossRef] [PubMed]
- Silva, M.I.G.; Aquino Neto, M.R.; Neto, P.F.T.; Moura, B.A.; do Amaral, J.F.; de Sousa, D.P.; Vasconcelos, S.M.M.; de Sousa, F.C.F. Central nervous system activity of acute administration of isopulegol in mice. Pharmacol. Biochem. Behav. 2007, 88, 141–147. [Google Scholar] [CrossRef] [PubMed]
- Xue, J.; Li, H.; Deng, X.; Ma, Z.; Fu, Q.; Ma, S. l-Menthone confers antidepressant-like effects in an unpredictable chronic mild stress mouse model via NLRP3 inflammasome-mediated inflammatory cytokines and central neurotransmitters. Pharmacol. Biochem. Behav. 2015, 134, 42–48. [Google Scholar] [CrossRef] [PubMed]
- Deng, X.Y.; Li, H.Y.; Chen, J.J.; Li, R.P.; Qu, R.; Fu, Q.; Ma, S.P. Thymol produces an antidepressant-like effect in a chronic unpredictable mild stress model of depression in mice. Behav. Brain Res. 2015, 291, 12–19. [Google Scholar] [CrossRef] [PubMed]
- Aquib, M.; Najmi, A.K.; Akhtar, M. Antidepressant effect of thymoquinone in animal models of depression. Drug Res. 2015, 65, 490–494. [Google Scholar] [CrossRef] [PubMed]
- Shoeb, A.; Chowta, M.; Pallempati, G.; Rai, A.; Singh, A. Evaluation of antidepressant activity of vanillin in mice. Indian J. Pharmacol. 2013, 45, 141–144. [Google Scholar] [PubMed]
- Lakusić, B.; Lakusić, D.; Ristić, M.; Marcetić, M.; Slavkovska, V. Seasonal variations in the composition of the essential oils of Lavandula angustifolia (Lamiacae). Nat. Prod. Commun. 2014, 9, 859–862. [Google Scholar] [PubMed]
- Liu, C.S.; Adibfar, A.; Herrmann, N.; Gallagher, D.; Lanctôt, K.L. Evidence for inflammation-associated depression. Curr. Top. Behav. Neurosci. 2017, 31, 3–30. [Google Scholar] [PubMed]
- De Moura, J.C.; Noroes, M.M.; Rachetti, V.P.S.; Soares, B.L.; Delia, P.; Nassini, R.; Materazzi, S.; Marone, I.M.; Minocci, D.; Geppetti, P.; et al. The blockade of transient receptor potential ankirin 1 (TRPA1) signalling mediates antidepressant- and anxiolytic-like actions in mice. Br. J. Pharmacol. 2014, 171, 4289–4299. [Google Scholar] [CrossRef] [PubMed]
- Riella, K.R.; Marinho, R.R.; Santos, J.S.; Pereira-Filho, R.N.; Cardoso, J.C.; Albuquerque-Junior, R.L.; Thomazzi, S.M. Anti-inflammatory and cicatrizing activities of thymol, a monoterpene of the essential oil from Lippia gracilis, in rodents. J. Ethnopharmacol. 2012, 143, 656–663. [Google Scholar] [CrossRef] [PubMed]
- Hasan, S.K.; Sultana, S. Geraniol attenuates 2-acetylaminofluorene induced oxidative stress, inflammation and apoptosis in the liver of wistar rats. Toxicol. Mech. Methods 2015, 25, 559–573. [Google Scholar] [PubMed]
- Koivisto, A.; Chapman, H.; Jalava, N.; Korjamo, T.; Saarnilehto, M.; Lindstedt, K.; Pertovaara, A. TRPA1: A transducer and amplifier of pain and inflammation. Basic Clin. Pharmacol. Toxicol. 2014, 114, 50–55. [Google Scholar] [CrossRef] [PubMed]
Essential Oils | Administration via and Duration of Treatment | Animal Specie | Dose Range Tested and Minimal Active Dose | Behavioral Test | Observed Effects | Mechanism of Action | Observations | Reference |
---|---|---|---|---|---|---|---|---|
Acorus tatarinowii Schott | Oral gavage, acute | ICR mouse | 30–240 mg/kg (60 mg/kg) | FST, TST | Reduced immobility time in both assays | DR+ | [33] | |
U-inverted curve | ||||||||
Controls: negative and positive (imipramine) | ||||||||
Asarum heterotropoides F. Schmidt | Inhalation, acute | ICR mouse | 0.25–2.0 g (0.25 g) | FST, TST | Reduced immobility time in both tests | Reversed the increase of CRF- and TH-positive cells in the paraventricular nucleus, and locus coeruleus, respectively; | DR+ Controls: negative and positive (fluoxetine) | [34] |
Reversed the decrease of 5-HT-positive cells in the dorsal raphe nucleus | ||||||||
Citrus limon (L.) Osbeck | Inhalation, acute | ICR mouse | Saturated chamber (90 min) | FST | Reduced immobility time | The treatment with flumazenil (GABAA antagonist), buspirone (5-HT1A partial agonist), DOI (5-HT2A receptor agonist), miaserin (5-HT2A/C receptor agonist), apomorphin (D receptor agonist) and haloperidol (D receptor antagonist) blocked the antidepressant effect. Increased hippocampal DA and prefrontal cortex and hippocampal 5-HT | DR− | [35] |
Controls: negative and positive (fluoxetine and imipramine) | ||||||||
Reduced spontaneous locomotor activity | ||||||||
Citrus limon (L.) Osbeck | Inhalation, acute | SD rats | Saturated chamber (60 min) | FST | Reduced immobility time | DR− | [36] | |
Controls: negative and positive (imipramine) | ||||||||
Reduced spontaneous locomotor activity | ||||||||
Citrus limon (L.) Osbeck | Oral gavage, 30 days | Swiss mouse | 50–150 mg/kg (50 mg/kg) | FST | Reduced immobility time | DR+ | [37] | |
Controls: negative and positive (imipramine and paroxetine) | ||||||||
The treatment decreased spontaneous locomotion increased sleeping duration | ||||||||
Eugenia uniflora L. | Oral gavage, acute | Swiss mouse | 1–50 mg/kg (10 mg/kg) | TST | Reduced immobility time | The blockade of 5-HT2A/C, α1 and α2-receptors prevented the antidepressant effects; | DR+ Controls: negative and positive (fluoxetine) | [38] |
In vitro inhibition of linoleic acid peroxidation; | ||||||||
Reduced SNP-induced lipoperoxidation in cortex, hippocampus and cerebellum | ||||||||
Lavandula angustifólia Mill. | Intraperitoneal, acute | SD rat | 5–20% (5%) | FST | Reduced immobility time | DR+ | [39] | |
Controls: negative and positive (fluoxetine and imipramine) | ||||||||
Lavandula angustifólia Mill. | Inhalation, acute | ICR mouse | Saturated chamber (90 min) | FST | No effects were observed | DR− | [35] | |
Controls: negative and positive (fluoxetine and imipramine) | ||||||||
Litsea glaucescens Kunth | Intraperitoneal, three times within 24 h | ICR mouse | 54.8–300 mg/kg (100 mg/kg) | FST | Reduced immobility time | DR+ | [40] | |
Controls: negative and positive (imipramine) | ||||||||
Mentha × piperita L. | Inhalation, acute | ICR mouse (female) | Saturated chamber (10 min) | FST | Reduced immobility time | DR− | [41] | |
Controls: negative | ||||||||
Perilla frutescens L. Britton | Oral gavage, 3 weeks | ICR mouse | 3–9 mg/kg (3 mg/kg) | CUMS, FST, TST, OFT | Restored sucrose preference in CUMS mice; | Reversed the 5-HT and 5-HIAA reduced concentrations in CUMS mice; Restored the serum IL-6, IL-1β, and TNF-α levels in CUMS mice | DR+ | [42] |
Reverted the reduced spontaneous locomotion in CUMS mice; | U-inverted curve | |||||||
Restored increased immobility time in CUMS mice | Controls: negative and positive (fluoxetine) | |||||||
Perilla frutescens L. Britton | Oral gavage, 3 and 4 weeks | ICR mouse | 3–6 mg/kg (3 mg/kg) | CUMS, FST, sucrose preference | Restored the CUMS-induced decreased sucrose preference and increased immobility time | Restored the CUMS-induced reduction of hippocampal protein and mRNA BDNF | DR+ | [43] |
Controls: negative and positive (fluoxetine) | ||||||||
Rosmarinus officinalis L. | Oral gavage, acute | Swiss mouse | 0.1–100 mg/kg (0.1 mg/kg) | TST | Reduced immobility time | DR+ | [44,45] | |
Controls: negative and positive (fluoxetine) | ||||||||
Rosmarinus officinalis L. | Intraperitoneal, acute | SD rat | 5–20% (5%) | FST | Reduced immobility time | DR+ | [39] | |
U-inverted curve | ||||||||
Controls: negative and positive (fluoxetine and imipramine) | ||||||||
Salvia sclarea L. | Intraperitoneal and inhalation, acute | SD rat | 5–20% (5%); satured chamber (1, 2, 4 and 6 h) | FST | Reduced immobility time when injected and inhaled | The pretreatment with haloperidol (Dopamine receptor antagonist), SCH-23390 (D1 receptor antagonist) and buspirone (5-HT1A partial agonist) blocked the antidepressant effect | DR+ | [39] |
Controls: negative and positive (fluoxetine and imipramine) | ||||||||
Schinus terebinthifolius Raddi | Oral gavage, 15 days | Wistar rats | 100 mg/kg | FST | Restored increased immobility time in rats subjected to a model of neuropathic pain | DR− | [46] | |
Controls: negative and positive (ketamine) | ||||||||
Syzygium aromaticum (L.) Merr, & L.M.Perry | Oral gavage, acute | ICR mouse | 50–200 mg/kg (100 mg/kg) | FST, TST | Reduced immobility time in both tests | DR+ | [47] | |
Controls: negative and positive (imipramine) LD50 = 45564.556 g/kg (po) | ||||||||
Syzygium aromaticum (L.) Merr, & L.M.Perry | Oral gavage, 5 weeks | SD rat | 50–200 mg/kg (50 mg/kg) | CUMS, novelty-suppressed feeding behavior | Restored sucrose preference in CUMS rats; Reverted the increased latency to feed in a unfamiliar environment in CUMS rats | Restored hippocampal BDNF protein, p-ERK and p-CREB expression | DR+ | [47] |
Controls: negative and positive (imipramine) | ||||||||
Thymus vulgaris L. (Lamiaceae) | Inhalation, acute | ICR mouse (female) | Saturated chamber (10 min) | FST | Reduced immobility time | DR− | [41] | |
Controls: negative | ||||||||
Toona ciliata Roem. var. yunnanensis (C. DC.) C.Y. WU | Oral gavage, acute | ICR mouse | 10–80 mg/kg (10 mg/kg) | FST, TST | Reduced immobility time in both tests | DR+ | [48] | |
Controls: negative and positive (imipramine) | ||||||||
Toona ciliata Roem var. yunnanensis (C. DC.) C.Y. WU | Oral gavage, acute | SD rat | 10–80 mg/kg (10 mg/kg) | CUMS | No behavioral effects were evaluated | Increased hippocampal monoamines (5-HT, NE and DA) and BDNF contents in CUMS rats; | DR+ Controls: negative and positive (imipramine) | [48] |
Reduced serum corticosterone in CUMS rats | ||||||||
Valeriana wallichii DC. | Oral gavage, acute and 14 days | Albino Laca mouse (male and female) | 10–40 mg/kg (10 mg/kg) | FST | Reduced immobility time | Increased noradrenaline and 5-HT levels after repeated administration; The acute antidepressant effect was prevented by pretreatment with L-arginine (NO precursor) and sildenafil (phosphodiesterase 5 inhibitor), while it was potentiated with L-NAME (NOS inhibitor) and methylene blue (inhibitor of soluble guanylate cyclase) | DR+ | [49] |
Controls: negative and positive (imipramine) | ||||||||
Zingiber officinale Roscoe | Inhalation, acute | ICR mouse (female) | Saturated chamber (10 min) | FST | Reduced immobility time | DR− | [41] | |
Controls: negative |
Constituents | Via of Administration and Duration of Treatment | Animal Specie | Dose Range Tested and Minimal Active Dose | Behavioral Test | Observed Effects | Mechanism of Action | Observations | Reference |
---|---|---|---|---|---|---|---|---|
Intraperitoneal, acute | ICR mouse | 5–20 mg/kg (10 mg/kg) | FST, TST | Reduced immobility time in both assays | DR+ | [33] | ||
Asarone | Controls: negative and positive (imipramine) | |||||||
Intraperitoneal, acute | C57BL/6 mouse | 50 mg/kg | FST, TST, novelty-suppressed feeding behavior | Reduced immobility time in the TST and the FST; decreased feeding latency in the novelty-suppressed feeding test | The pretreatment with AM630 (CB2 antagonist) prevented the anti-immobility effects | DR− | [52] | |
β-Caryophyllene | Controls: negative | |||||||
Oral gavage, acute | Swiss mouse | 12.5–50 mg/kg (12.5 mg/kg) | FST, TST | Reduced immobility time in both tests | The pretreatment with SCH23390 (D1 antagonist) and sulpiride (D2 antagonist) prevented the anti-immobility effects | DR+ | [68] | |
Carvacrol | Controls: negative and positive (imipramine) | |||||||
Oral gavage, 21 days | SD rat, 18 months old | 22.5–90 mg/kg (45 mg/kg) | CUMS | Reversed decreased sucrose preference and spontaneous locomotion in CUMS rats | Reversed the increased hippocampal COX-2 protein and activity; Reversed the elevated PGE2 concentration in frontal cortex and hippocampus in CUMS rats | DR+ | [69] | |
Cinnamic aldehyde | Controls: negative and positive (fluoxetine) | |||||||
Inhalation, acute | SD rats | Saturated chamber (60 min) | FST | Reduced immobility time | DR− | [36] | ||
Controls: negative and positive (imipramine) | ||||||||
Citral | Hypolocomotion | |||||||
Intraperitoneal, acute | Wistar rat | 0.1–0.3 g/kg | FST | No effects | DR+ | [45,70] | ||
γ-Decanolactone | Controls: negative Hypolocomotion at higher doses | |||||||
Intraperitoneal, three times within 24 h | ICR mouse | 100 mg/kg | FST | No effects | DR− | [40] | ||
Eucalyptol | Controls: negative and positive (imipramine) | |||||||
Intraperitoneal, 14 days | ddY mice | 10–100 mg/kg (30 mg/kg) | FST, TST | Reduced immobility time in the TST and increased number of wheel rotations in the FST | Increased Hippocampal BDNF and metallothionein-III (brain-predominant protein that alleviates various neurotoxic events) mRNA | DR+ | [61] | |
Controls: negative and positive (imipramine) | ||||||||
Eugenol | Oral, mixed with drinking water, 14 days | ICR mouse | 0.17 mmol/kg | FST | Increased number of wheel rotations in the FST | Inhibits human MAOA (IC50 34.4 µM) preferencially than MAOB (IC50 288 µM) activity | DR− | [62] |
Controls: negative | ||||||||
Oral gavage, 4 weeks | ICR mouse | 20–40 mg/kg (20 mg/kg) | CUMS, FST, TST | Restored decreased sucrose preference and increased immobility time in the TST and FST in mice subjected to CUMS | Reversed the IL-1β-related CNS inflammation by markedly inhibiting CUMS-induced PFC NF-κB pathway and modulating NLRP3 inflammasome activation (activated caspase 1) in CUMS mice | DR+ | [60] | |
Geraniol | Controls: negative and positive (fluoxetine) | |||||||
Intraperitoneal, acute | Swiss mouse | 25–50 mg/kg (25 mg/kg) | FST, TST | Increased immobility time | DR+ | [71] | ||
Isopulegol | Controls: negative and positive (imipramine) | |||||||
Oral gavage, 15 days | Wistar rat | 10 mg/kg | FST | Restored increased immobility time in rats subjected to a model of neuropathic pain | DR− | [46] | ||
Controls: negative and positive (ketamine) | ||||||||
Limonene | Intraperitoneal, three times within 24 h | ICR mouse | 100 mg/kg | FST | No effects | DR− | [40] | |
Controls: negative and positive (imipramine) | ||||||||
Linalool | Intraperitoneal, three times within 24 h | ICR mouse | 54.8–173.2 mg/kg (100 mg/kg) | FST | Reduced immobility time | DR+ | [40] | |
U-inverted curve | ||||||||
Controls: negative and positive (imipramine) | ||||||||
The treatment reduced spontaneous locomotion | ||||||||
Intraperitoneal, three times within 24 h | ICR mouse | 100 mg/kg | FST | Reduced immobility time | The pretreatment with WAY100,635 (5-HT1A antagonist) and yohimbine (α2-antagonist) prevented the antidepressant-like effects | DR− | [58] | |
Controls: negative and positive (imipramine) | ||||||||
Intraperitoneal, acute | Swiss mouse | 10–200 mg/kg (100 mg/kg) | TST | Reduced immobility time | DR+ | [59] | ||
Controls: negative and positive (imipramine) | ||||||||
Oral gavage, 3 weeks | ICR mouse | 15–30 mg/kg (15 mg/kg) | CUMS, FST, TST | Reversed the decrease of sucrose consumption, the hypolocomotion and the increased immobile time in the TST and FST in CUMS mice | Restored the CUMS-induced reductions in hippocampal NE and 5-HT levels; Reverted the increased hippocampal pro-inflammatory cytokines levels (IL-1β, IL-6, and TNFα) in CUMS mice; Inhibited the increased hippocampal nod-like receptor protein 3 (NLRP3) inflammasome, and caspase-1 protein expression in CUMS mice | DR+ | [72] | |
Menthone | Controls: negative and positive (fluoxetine) | |||||||
Oral gavage, acute | Wistar rats | 1.0–10.0 µl/mL/kg (1.0 µl/mL/kg) | FST | Reduced immobility time | DR+ | [50] | ||
Methyl-eugenol | Controls: negative | |||||||
Intraperitoneal, three times within 24 h | ICR mouse | 100 mg/kg | FST | No effects | DR− | [40] | ||
α-Pinene | Controls: negative and positive (imipramine) | |||||||
β-Pinene | Intraperitoneal, three times within 24 h | ICR mouse | 54.8–173.2 mg/kg (100 mg/kg) | FST | Reduced immobility time | DR+ | [40] | |
Controls: negative and positive (imipramine) | ||||||||
The treatment reduced the spontaneous locomotion | ||||||||
Intraperitoneal, three times within 24 h | ICR mouse | 100 mg/kg | FST | Reduced immobility time | The pretreatment with WAY100,635 (5-HT1A antagonist), propranolol (β-antagonist), DSP-4 (NE neurotoxin), SCH23390 (D1 antagonist) prevented the anti-immobility effect | DR− | [58] | |
Controls: negative and positive (imipramine) | ||||||||
Oral gavage, 7 days | ICR mouse | 60–120 mg/kg (60 mg/kg) | LPS-induced depressant-like behavior, FST and TST | Reversed increased in immobility time in the FST and TST in LPS-treated mice | Reversed the reduced concentrations of 5-HT and NE, and attenuated LPS-induced increases of serum protein levels and prefrontal cortex mRNA of TNF-α and IL-6 | DR+ | [70] | |
Controls: negative and positive (fluoxetine) | ||||||||
Perillaldehyde | Inhalation, 9 days | ddY mouse | 0.1–10% dropped on the area between eyes and nose (1%) | CUMS, FST | Reduced immobility time in naïve mouse and reversed increased immobility time in CUMS mice | DR+ | [57] | |
Controls: negative and positive (minalcipran) | ||||||||
Oral gavage, once daily, 15 days | Wistar rat | 10 mg/kg | FST | Restored increased immobility time in rats subjected to a model of neuropathic pain | DR− | [46] | ||
α-Phellandrene | Controls: negative and positive (ketamine) | |||||||
Oral gavage, 3 weeks | ICR mouse | 15–30 mg/kg (15 mg/kg) | CUMS, TST, FST | Reversed the decrease of sucrose consumption, the loss of body weight, and the increased immobile time in the TST and FST in CUMS mice | Restored the CUMS-induced reductions in hippocampal NE and 5-HT; Reverted the increased hippocampal mRNA of pro-inflammatory cytokines (IL-1β, IL-6, and TNFα) in CUMS mice; Inhibited the activation of nod-like receptor protein 3 (NLRP3) inflammasome and its adaptor, and subsequently decreased the expression of caspase-1 | DR+ | [73] | |
Thymol | Controls: negative and positive (fluoxetine) | |||||||
Intraperitoneal, acute | Swiss mouse | 20 mg/kg | FST, TST | Reduced immobility time in both tests | A significant elevation of 5-HT whole brain levels was observed; Increased glutathione levels and decreased TBARS levels in the whole brain | DR− | [74] | |
Thymoquinone | Controls: negative and positive (fluoxetine) | |||||||
Oral gavage, acute and 10 days | Swiss mouse (male and female) | 10–100 mg/kg (10 mg/kg) | FST, TST | Reduced immobility time under acute and chronic treatments | DR+ | [75] | ||
Vanillin | Controls: negative and positive (fluoxetine and imipramine) |
© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
De Sousa, D.P.; Silva, R.H.N.; Silva, E.F.d.; Gavioli, E.C. Essential Oils and Their Constituents: An Alternative Source for Novel Antidepressants. Molecules 2017, 22, 1290. https://doi.org/10.3390/molecules22081290
De Sousa DP, Silva RHN, Silva EFd, Gavioli EC. Essential Oils and Their Constituents: An Alternative Source for Novel Antidepressants. Molecules. 2017; 22(8):1290. https://doi.org/10.3390/molecules22081290
Chicago/Turabian StyleDe Sousa, Damião P., Rayanne H. N. Silva, Epifanio F. da Silva, and Elaine C. Gavioli. 2017. "Essential Oils and Their Constituents: An Alternative Source for Novel Antidepressants" Molecules 22, no. 8: 1290. https://doi.org/10.3390/molecules22081290
APA StyleDe Sousa, D. P., Silva, R. H. N., Silva, E. F. d., & Gavioli, E. C. (2017). Essential Oils and Their Constituents: An Alternative Source for Novel Antidepressants. Molecules, 22(8), 1290. https://doi.org/10.3390/molecules22081290